Patents Assigned to Gilead Sciences, Inc.
  • Combination therapy comprising an ACC inhibitor
    Patent number: 11963961
    Abstract: The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie Geier Bates, Adrian S. Ray
  • Phospholipid compounds and uses thereof
    Patent number: 11963967
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • Combination MCL-1 inhibitors with anti-cancer agents
    Patent number: 11957693
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: April 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11944611
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 2, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
  • 1?-cyano nucleoside analogs and uses thereof
    Patent number: 11939347
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich
  • LPA receptor antagonists and uses thereof
    Patent number: 11939318
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Barton W. Phillips, Kin S. Yang, Anna Zagorska
  • Diacylglycerol kinase modulating compounds
    Patent number: 11932634
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Juan A. Guerrero, Stephen D. Holmbo, Jesse M. Jacobsen, Tetsuya Kobayashi, Leena B. Patel, Heath A. Weaver, Jie Xu, Suet C. Yeung
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Substituted 6-azabenzimidazole compounds
    Patent number: 11925631
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L. Cosman, Rao V. Kalla, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Joshua J. Van Veldhuizen, Suet C. Yeung, Jeff Zablocki
  • Compounds and methods for treatment of viral infections
    Patent number: 11926645
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C. Hui, Rao V. Kalla, Richard L. Mackman
  • Diacylglyercol kinase modulating compounds
    Patent number: 11926628
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Jesse M. Jacobsen, Tetsuya Kobayashi, Jonathan William Medley, Yasamin Moazami, Leena B. Patel, Jie Xu, Suet C. Yeung
  • CD73 compounds
    Patent number: 11919869
    Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: March 5, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Richard L Mackman, Michael R. Mish, Dustin S. Siegel, Kyle C. Tamshen, Hai Yang
  • METHODS OF TREATING NASH
    Publication number: 20240066016
    Abstract: The present disclosure relates generally to methods of using modulators of COT (cancer Osaka thyroid) for treating, stabilizing, or lessening the severity or progression of liver disease, in particular, Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
    Type: Application
    Filed: September 25, 2023
    Publication date: February 29, 2024
    Applicant: Gilead Sciences, Inc.
    Inventors: David G. Breckenridge, Grant R. Budas, Ruchi Gupta, James G. Taylor, Matthew R. Warr, Nathan E. Wright
  • LPA receptor antagonists and uses thereof
    Patent number: 11912686
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: February 27, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Julie Farand, Doris T. Tang, Kin S. Yang
  • Cot modulators and methods of use thereof
    Patent number: 11905299
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Remdesivir treatment methods
    Patent number: 11903953
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Substituted 6-azabenzimidazole compounds
    Patent number: 11897878
    Abstract: The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Mark J. Bartlett, Jayaraman Chandrasekhar, Julian A. Codelli, John H. Conway, Jennifer L Cosman, Rao V. Kalla, Zachary A. Kasun, Musong Kim, Seung H. Lee, Jennifer R. Lo, Jennifer A. Loyer-Drew, Scott A. Mitchell, Thao D. Perry, Gary B. Phillips, Patrick J. Salvo, Sundaramoorthi Swaminathan, Joshua J. Van Veldhuizen, Suet C Yeung, Jeff Zablocki
  • IKAROS zinc finger family degraders and uses thereof
    Patent number: 11897862
    Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.
    Type: Grant
    Filed: April 7, 2023
    Date of Patent: February 13, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gayatri Balan, Peter A. Blomgren, Chen Chen, Julian A. Codelli, Zhimin Du, Musong Kim, Dorothée Saddier Axe, Gregg M. Schwarzwalder, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani, William J. Watkins, Brian M. Weist, Suet C. Yeung, Helen Yu
  • Pharmaceutical package
    Patent number: D1016608
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: March 5, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Benjamin Luke Kozub, Brian Nilstoft, Kevin Nguyen, James Paul Oberhauser, Roman Shumylo, Joseph Anthony Cordova, Jinhui Yun, William Harold Lizor, Jr., Adam Hilborn, Jesse Arnold Fourt, Léo Boris Marzolf, Pratap Uday Ganapathy, Brooke Genelle Thyng, Caricia Catalani, Soizic Porhel, Jose Angel Meza, Steven M. Scally, Mary Cassandra Lodwick
  • Pharmaceutical package
    Patent number: D1019381
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: March 26, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Benjamin Luke Kozub, Brian Nilstoft, Kevin Nguyen, James Paul Oberhauser, Roman Shumylo, Joseph Anthony Cordova, Jinhui Yun, William Harold Lizor, Jr., Adam Hilborn, Jesse Arnold Fourt, Léo Boris Marzolf, Pratap Uday Ganapathy, Brooke Genelle Thyng, Caricia Catalani, Soizic Porhel, Jose Angel Meza, Steven M. Scally, Mary Cassandra Lodwick